TY - JOUR
T1 - Gastrointestinal Stromal Tumors. Molecular Markers and Genetic Subtypes
AU - Barnett, Christine M.
AU - Corless, Christopher L.
AU - Heinrich, Michael C.
N1 - Funding Information:
Disclosures: None (C.M. Barnett); honoraria from Novartis; consulting fees from Novartis and Pfizer ; research support from Novartis, Pfizer, and Bayer (C.L. Corless); honoraria from Onyx; consulting fees from Novartis, Pfizer, Ariad , MolecularMD ; research support from Novartis, Pfizer, AROG , Ariad, Imclone ; equity interest: MolecularMD (M.C. Heinrich).
PY - 2013/10
Y1 - 2013/10
N2 - Mutation-activated signaling from the KIT and PDGFRA kinases has been successfully targeted in gastrointestinal stromal tumors (GISTs), with subtle differences between the mutations serving to refine prognosis and more precisely tailor therapy. There is a growing understanding of the molecular drivers of GISTs lacking mutations in KIT or PDGFRA, so called wild-type GISTs, further aiding in management decisions. This article provides an overview of all the known molecular subtypes of GIST and provides information about clinical correlates, treatment, and prognosis depending on the subtype.
AB - Mutation-activated signaling from the KIT and PDGFRA kinases has been successfully targeted in gastrointestinal stromal tumors (GISTs), with subtle differences between the mutations serving to refine prognosis and more precisely tailor therapy. There is a growing understanding of the molecular drivers of GISTs lacking mutations in KIT or PDGFRA, so called wild-type GISTs, further aiding in management decisions. This article provides an overview of all the known molecular subtypes of GIST and provides information about clinical correlates, treatment, and prognosis depending on the subtype.
KW - GIST
KW - KIT
KW - PDGFRA
KW - RTK-wild-type
KW - SDH
UR - http://www.scopus.com/inward/record.url?scp=84884975893&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84884975893&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2013.07.003
DO - 10.1016/j.hoc.2013.07.003
M3 - Review article
C2 - 24093165
AN - SCOPUS:84884975893
SN - 0889-8588
VL - 27
SP - 871
EP - 888
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 5
ER -